Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis

Medical Mycology

Volumn 50, Issue 4, 2012, Pages 353-360

  Tashiro, Masato ^a,b   Kimura, Soichiro ^a   Tateda, Kazuhiro ^a   Saga, Tomoo ^a   Ohno, Akira ^a   Ishii, Yoshikazu ^a   Izumikawa, Koichi ^b   Tashiro, Takayoshi ^b   Kohno, Shigeru ^b   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Candida albicans; Farnesol; Mouse; Statin; Systemic candidiasis

Indexed keywords

FARNESOL; FLUCONAZOLE; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MOUSE; FUNGAL VIRULENCE; FUNGUS ISOLATION; GROWTH INHIBITION; IN VITRO STUDY; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; TREATMENT RESPONSE;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FARNESOL; FEMALE; MICE; MICE, INBRED C3H; PRAVASTATIN; SURVIVAL ANALYSIS; VIRULENCE FACTORS;

CANDIDA; CANDIDA ALBICANS;

EID: 84859774407     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.610037     Document Type: Article

References (29)

1. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55 : 809-818. (Pubitemid 43974685)
2. Antimicrobial Agents and Chemotherapy. New antimicrobial agents approved by the U.S. Food and Drug Administration in 2004 and new indications for previously approved agents. Antimicrob Agents Chemother 2005; 49 : 2151.
3. Antimicrobial Agents and Chemotherapy. New antimicrobial agents approved by the U.S. Food and Drug Administration in 2005 and new indications for previously approved agents. Antimicrob Agents Chemother 2006; 50 : 1912.
4. Antimicrobial Agents and Chemotherapy. New antimicrobial agents approved by the U.S. Food and Drug Administration in 2006 and new indications for previously approved agents. Antimicrob . Agents Chemother 2007; 51 : 2649.
5. Horn DL, Neofytos D, Anaissie EJ, et al . Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48 : 1695-1703.
6. Espinel-Ingroff A. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005 - 2009). Rev Iberoam Micol 2009; 26 : 15-22.
7. Kitamura A, Higuchi S, Hata M, et al . Effect of beta-1,6-glucan inhibitors on the invasion process of Candida albicans : potential mechanism of their in vivo effi cacy. Antimicrob Agents Chemother 2009; 53 : 3963-3971.
8. Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis. Antimicrob Agents Chemother 2009; 53 : 670-677.
9. Chin NX, Weitzman I, Della-Latta P. I n vitro activity of fl uvastatin, a cholesterol-lowering agent, and synergy with fl ucanazole and itraconazole against Candida species and Cryptococcus neoformans . Antimicrob Agents Chemother 1997; 41 : 850-852. (Pubitemid 27150546)
10. Gyetvai A, Emri T, Takacs K, et al . Lovastatin possesses a fungistatic effect against Candida albicans , but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res 2006; 6 : 1140-1148. (Pubitemid 44800311)
11. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006; 262 : 9-13. (Pubitemid 44212883)
12. Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fl uconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans . Med Mycol 2003; 41 : 417-425. (Pubitemid 37441445)
13. Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata . FEMS Yeast Res 2007; 7 : 436-441. (Pubitemid 46555514)
14. Nyilasi I, Kocsube S, Krizsan K, et al . In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett 2010; 307 : 175-184.
15. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis 2010; 10 : 152.
16. Navarathna DH, Hornby JM, Krishnan N, et al . Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans . Infect Immun 2007; 75 : 1609-1618. (Pubitemid 46559424)
17. Hampton R, Dimster-Denk D, Rine J. The biology of HMG-CoA reductase: the pros of contra-regulation. Trends Biochem Sci 1996; 21 : 140-145. (Pubitemid 26104406)
18. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts . Approved standard M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
19. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48 : 693-715. (Pubitemid 38280314)
20. Hornby JM, Jensen EC, Lisec AD, et al . Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67 : 2982-2992. (Pubitemid 33644762)
21. Nash JD, Burgess DS, Talbert RL. Effect of fl uvastatin and pravastatin, HMG-CoA reductase inhibitors, on fl uconazole activity against Candida albicans . J Med Microbiol 2002; 51 : 105-109. (Pubitemid 34136744)
22. Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW. Farnesol concentrations required to block germ tube formation inCandida albicans in the presence and absence of serum. Appl Environ Microbiol 2005; 71 : 4938-4940. (Pubitemid 41129562)
23. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. Inhibition of Candida albicans biofi lm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68 : 5459-5463. (Pubitemid 35265681)
24. Navarathna DHMLP, Hornby JM, Hoerrmann N, e t al . Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fl uconazole in a mouse model of disseminated candidiasis. J Antimicrob Chemother 2005; 56 : 1156-1159. (Pubitemid 43009840)
25. Komai T, Kawai K, Tokui T, et al . Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 1992; 17 : 103-113.
26. Galgoczy L, Nyilasi I, Papp T, Vagvolgyi C. Are statins applicable for the prevention and treatment of zygomycosis? Clin Infect Dis 2009; 49 : 483; author reply 484-485.
27. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth 2008; 100 : 288-298. (Pubitemid 351773654)
28. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifi cations at multiple levels. Lancet Infect Dis 2007; 7 : 358-368. (Pubitemid 46590065)
29. Ghosh S, Howe N, Volk K, et al . Candida albicans cell wall components and farnesol stimulate the expression of both infl ammatory and regulatory cytokines in the murine RAW264.7 macrophage cell line. FEMS Immunol Med Microbiol 2010; 60 : 63-73.